Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/4/2017
SIETES contiene 91761 citas

 
 
 1 a 20 de 503 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
2. Cita con resumen
Erviti López J, Saiz Fernández LC, Garjón Parra J. Fiabilidad de los ensayos clínicos. El peligroso camino de la desregulación de los medicamentos. Med Clin (Barc) 2016;147:554-7. [Ref.ID 101012]
4. Cita con resumen
Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 2016;176:1826-33. [Ref.ID 100788]
5. Cita con resumen
Golder S , Loke YK , Wright K , Norman G. ) Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review . PLOS Medicine 2016;13:e1002127. [Ref.ID 100696]
7.Tiene citas relacionadas Cita con resumen
Jureidini J. Antidepressants fail, but no cause for therapeutic gloom. Lancet 2016;388:844-5. [Ref.ID 100611]
8. Cita con resumen
Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, Murugiah K, Lu DY, Mittal A, Krumholz HM, Hines HH. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ 2016;352:i637. [Ref.ID 100065]
9. Cita con resumen
Derry S, Wiffen P, Moore A. Topical nonsteroidal anti-inflammatory drugs for acute musculoskeletal pain. JAMA 2016;315:813-4. [Ref.ID 100022]
10. Cita con resumen
Gubar S. Living with cancer: a broken covenant with patients. N Y Times (Print) 2016:1. [Ref.ID 99979]
11.Enlace a cita original Cita con resumen
Jefferson T. Qué hacer ante la desconfianza en los ensayos clínicos publicados. Boletín de Información Farmacoterapéutica de Navarra 2015;23:1-12. [Ref.ID 99656]
12. Cita con resumen
Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015;351:h4320. [Ref.ID 99581]
13. Cita con resumen
Dyer O. Drug maker must restart obesity drug study after releasing early data. BMJ 2015;350:h2844. [Ref.ID 99103]
14. Cita con resumen
Dyer O. Major publisher retracts 43 papers, alleging fake peer review. BMJ 2015;350:h1783. [Ref.ID 98943]
15. Cita con resumen
Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 2015;372:1031-9. [Ref.ID 98939]
16. Cita con resumen
Hakala A, Kimmelman J, Carlisle B, Freeman G, Fergusson D. Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. BMJ 2015;350:h1116. [Ref.ID 98841]
17. Cita con resumen
Gulland A. WHO urges reporting of clinical trials within 18 months. BMJ 2014;349:g6292. [Ref.ID 98285]
18.Tiene citas relacionadas Cita con resumen
19.Tiene citas relacionadas Cita con resumen
Maund E, Tendal B, Hróbjartsson A, Jorgensen KJ, Lundh A, Schroll J, Gotzsche PC. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ 2014;348:g3510. [Ref.ID 98036]
20.Tiene citas relacionadas Cita con resumen
Doshi P, Zito J, dosReis S. Digging for data on harms in duloxetine trials. BMJ 2014;348:g3578. [Ref.ID 98035]
Seleccionar todas
 
 1 a 20 de 503 siguiente >>